Structure via PubChem · Public domain (PubChem)
zuclopenthixol
Sign in to saveAlso known as cis(Z)-cloflupentixol, Cisordinol®, Clopixol®, NSC 64087, NSC169185, (Z)-4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol, Zuclopenthixolum
Zuclopenthixol (brand names Cisordinol, Clopixol and others), also known as zuclopentixol, is a medication used to treat schizophrenia and other psychoses. It is classed, pharmacologically, as a typical antipsychotic. Chemically it is a thioxanthene. It is the cis-isomer of clopenthixol (Sordinol, Ciatyl). Clopenthixol was introduced in 1961, while zuclopenthixol was introduced in 1978.
Chemical data
- Formula
- C22H25ClN2OS
- Molecular weight
- 401 g/mol
- IUPAC name
- 2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol
- SMILES
- C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
- InChIKey
- WFPIAZLQTJBIFN-DVZOWYKESA-N
- XLogP
- 4.3
- Polar surface area
- 52 Ų
- H-bond donors
- 1
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- clopenthixol
- Mass
- 400.137612
- Has use
- medication
Show 8 more facts
- chemical formula
- C₂₂H₂₅ClN₂OS
- canonical SMILES
- C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
- isomeric SMILES
- C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
- World Health Organisation international non-proprietary name
- zuclopenthixol
- Commons category
- Zuclopenthixol
- defined daily dose
- 30
- significant drug interaction
- lithium
- safety classification and labelling
- Regulation (EC) No. 1272/2008
via Wikidata · CC0
~7 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Available forms
- Dosing
- Side effects
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- History
- References
Zuclopenthixol (brand names Cisordinol, Clopixol and others), also known as zuclopentixol, is a medication used to treat schizophrenia and other psychoses. It is classed, pharmacologically, as a typical antipsychotic. Chemically it is a thioxanthene. It is the cis-isomer of clopenthixol (Sordinol, Ciatyl). Clopenthixol was introduced in 1961, while zuclopenthixol was introduced in 1978.
Zuclopenthixol is a D1 and D2 antagonist, α1-adrenergic and 5-HT2 antagonist. While it is approved for use in Australia, Canada, Ireland, India, New Zealand, Singapore, South Africa and the UK, it is not approved for use in the United States.
Excerpted from Wikipedia’s “zuclopenthixol” article, available under the CC BY-SA 4.0 licence.